Objective To examine disparities in delivery of care and survival according to racial classification among White and African-American women with Stage IIIC epithelial ovarian cancer undergoing initial treatment in a tertiary referral center setting. Methods All consecutive patients diagnosed with Stage IIIC epithelial ovarian cancer between 1/1/95 and 12/31/08 were identified and clinic-pathologic variables retrospectively collected. Differences in initial treatment paradigm, surgical and adjuvant therapy, and overall survival according to racial classification were assessed by univariate and multivariate analyses. Results A total of 405 patients (White, n = 366; African-American, n = 39) were identified. There were no significant differences according to racial classification in age, CA125, ASA class, histology, tumor grade, the frequency of initial surgery (90.4% vs 82.1%, p = 0.06), optimal residual disease (73.0% vs 69.2%, p = 0.28), no gross residual disease (51.4% vs 53.8%, p = 0.49), and platinum-taxane chemotherapy (88.3% vs 87.2%, p = 0.55). The median overall survival for White patients was 50.5 months (95%CI = 43.2–57.9 months), compared to 47.0 (95%CI = 36.2–57.8) months for African-Americans ( p = 0.57). On multivariate analysis, age, tumor grade 3, serum albumin < 3.0 g/dl, platinum-based chemotherapy, and no gross residual disease were independently associated with overall survival, while African-American race was not (HR = 1.06, 95%CI = 0.61–1.79). Conclusions Among women undergoing initial treatment for ovarian cancer at a tertiary referral center, African-American patients were as likely as White patients to undergo cytoreductive surgery, be left with minimal post-surgical residual disease, and receive appropriate chemotherapy. With equal access to gynecologic oncology care and multidisciplinary cancer resources, the survival disparities according to race observed in population-based studies are largely mitigated.